The milestone shows Epix and Cystic Fibrosis Foundation Therapeutics’s (CFFT) successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein. A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with cystic fibrosis.
Michael Kauffman, CEO of Epix, said: “Our collaboration with CFFT has now resulted in four achieved milestones in two years and further validates our computational-medicinal chemistry approach to drug discovery. This new, complete model of CFTR will allow us to prepare for the lead optimization process and further advance our research efforts in cystic fibrosis.”